| Stereochemistry | ABSOLUTE |
| Molecular Formula | C42H36N10O10S |
| Molecular Weight | 872.861 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
NC(=O)CC[C@H](N(CCNC(=S)NC1=CC=C2C(=C1)C(=O)OC23C4=C(OC5=C3C=CC(O)=C5)C=C(O)C=C4)C(=O)C6=CC=C(NCC7=NC8=C(N=C7)N=C(N)NC8=O)C=C6)C(O)=O
InChI
InChIKey=ZMTAPBHUSYTHBY-PMERELPUSA-N
InChI=1S/C42H36N10O10S/c43-33(55)12-11-30(38(58)59)52(37(57)20-1-3-21(4-2-20)46-18-23-19-47-35-34(48-23)36(56)51-40(44)50-35)14-13-45-41(63)49-22-5-8-27-26(15-22)39(60)62-42(27)28-9-6-24(53)16-31(28)61-32-17-25(54)7-10-29(32)42/h1-10,15-17,19,30,46,53-54H,11-14,18H2,(H2,43,55)(H,58,59)(H2,45,49,63)(H3,44,47,50,51,56)/t30-/m0/s1
EC17 (also known as Folate-FITC) is conjugate consisting of fluorescein isothiocyanate (FITC) conjugated with folate with potential antineoplastic activity. EC17 binds to folate receptors, which are overexpressed on the surfaces of many cancer cells including kidney and ovarian cancer cells. Once bound to the cancer cell through the folate moiety of the conjugate, circulating anti-fluorescein antibodies recognize and bind to the FITC moiety, resulting in antibody-dependent cellular cytotoxicity. EC17 is participating in phase II clinical trials for the treatment of patients with endometrial cancer, endometriosis, lung cancer, renal cell carcinoma. In January 2018, On Target Laboratories initiated a phase III trial to evaluate the safety and efficacy of EC17 injection for patients with ovarian cancer.
Originator
Approval Year
PubMed
ACTIVE MOIETY
